TuHURA Biosciences获FDA孤儿药认定 IFX-2.0有望治疗IIb至IV期皮肤黑色素瘤

美股速递
Feb 02

TuHURA Biosciences, Inc. (以下简称TuHURA) 宣布,其研发的候选药物IFX-2.0已获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定,适应症为IIb期至IV期皮肤黑色素瘤。

孤儿药认定旨在鼓励针对罕见病的新药研发。获得该认定意味着IFX-2.0在针对这一特定阶段的黑色素瘤治疗方面,有望在药物开发及后续商业化进程中享受一系列政策支持,包括临床试验费用税收抵免、FDA用户费减免以及药物获批后七年的市场独占权。

此次认定标志着IFX-2.0在治疗晚期皮肤黑色素瘤的研发道路上迈出了重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10